GALENICA AG

Galenica AG hits 7.1% sales growth in H1‑2026, driven by Home Care, Diagnostics and wholesale, affirming robust Swiss pharmacy leadership.

Discover how Galenica AG’s strategic growth, strong 4.17 bn CHF market cap and 22.77 P/E are reshaping Swiss healthcare and boosting investor confidence.

Galenica AG reports 11 % EBIT rise and 9 % dividend growth, ups mid‑term outlook, focuses on retail expansion and digital services after closing Bichsel’s plant.

Galenica AG tops 2025 expectations, boosting revenue, EBIT, and cash flow, and lifting 2026–27 guidance, driven by pharmacy, wholesale, and diagnostics growth.

Galenica AG posts record CHF 4.136 bn revenue, a 5.5 % rise, driven by omnichannel pharmacy growth and expanding diagnostics, boosting investor confidence and future EBIT1 prospects.

Galenica AG raises CHF 250 m with a 1.08 % bond to fund its Labor Team Group acquisition, strengthen its balance sheet and fuel future Swiss retail expansion.